Question to the Department of Health and Social Care:

To ask Her Majesty's Government what plans they have to lift the ban on the pharmaceutical use of pooled plasma from UK donors; and what assessment they have made of the impact of allowing the use of such plasma on national self-sufficiency in immunoglobulin and other plasma-derived medicinal products.

The safety of United Kingdom plasma is reviewed periodically. A comprehensive review of the safety of immunoglobulins produced from fractionated UK plasma was conducted by the Medicines and Healthcare products Regulatory Agency (MHRA) during 2020 and is now under consideration by the Department and the devolved administrations.

The Department will work with the devolved administrations, NHS England and NHS Improvement, the MHRA and NHS Blood and Transplant to consider the implications of any decision on the UK supply of plasma for immunoglobulin.